Progyny, Inc. PGNY

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Progyny has delivered a mixed ride for shareholders, with the stock climbing over the past year but still showing a steep decline over five years. This puts a sharper spotlight on what investors are really paying for its earnings today. With that backdrop, the key issue is whether the current share price around US$27 fairly reflects the company’s profit engine. Over the past 5 years, Progyny’s share price has fallen 57.5%, which raises the question of whether the market is reassessing how...

Let’s dig into the relative performance of Progyny (NASDAQ:PGNY) and its peers as we unravel the now-completed Q2 health insurance providers earnings season.

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://inves

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

MNDY, MTCH, PGNY and WK make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.

What employees really want are fertility benefits, and there’s a market for providing them that’s underserved. Progyny provides family-focused services to about 7 million patients at more than 600 companies, but Wells Fargo sees a potential market of 156 million. The decade-old company made nearly $1.3 billion in revenue in the past fiscal year, up 10%, as it continued expanding beyond basic fertility services. Sign up for The Daily Upside at no cost for premium analysis on all your favorite stocks.

Progyny’s second quarter results were met with a negative market reaction, despite the company delivering revenue and non-GAAP profit above Wall Street expectations. CEO Peter Anevski attributed the quarter’s growth to continued demand from employers for family building and women’s health solutions, emphasizing strong retention and early client commitments. Management noted that higher engagement levels and operational efficiencies contributed to margin expansion, while a more pronounced summer

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Shares of fertility benefits company Progyny (NASDAQ:PGNY) fell 4.5% in the afternoon session after the company issued a weak forecast, overshadowing second-quarter results that beat expectations.

Progyny stock has delivered a 38.8% decline over the past five years, even though the valuation checks currently suggest the shares may be pricing in cautious expectations. Recent gains over the last year now sit alongside a high value score and a recent pullback, which raises questions about how the market is weighing Progyny's long term prospects against its current valuation. Over the past five years, Progyny has declined 38.8%. This shows that long term holders have faced a material...